Atrium Therapeutics, Inc. develops Antibody Oligonucleotide Conjugates (AOCs), a class of RNA therapeutics that combine the tissue selectivity of monoclonal antibodies with the precision of oligonucleotide therapies to target genetic drivers of disease. The company’s pipeline focuses on rare muscle diseases, including myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Duchenne muscular dystrophy (DMD). Its lead product candidate, del-desiran (AOC 1001), is in Phase 3 clinical trials for DM1, while del-brax (AOC 1020) is in Phase 1/2 for FSHD and del-zota (AOC 1044) is in Phase 2 for DMD. The company utilizes its proprietary AOC platform to deliver RNA into muscle tissue, aiming to treat conditions previously inaccessible to standard RNA therapies.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Biotechnology Homepage aviditybiosciences.com
Sector Healthcare IR page investors.atriumtherapeutics.com
Tags
rna therapeutics, antibody oligonucleotide conjugates, rare muscle diseases, myotonic dystrophy, duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, gene therapy, clinical stage, AOC, del-desiran, AOC 1001, HARBOR, MARINA-OLE, MARINA, del-brax, AOC 1020, FORTITUDE, del-zota, AOC 1044, EXPLORE44-OLE
Press page —

Metrics

Valuation  
Market cap $ 220.593M
Market cap (USD) $ 220.593M
P/E —
PEG —
P/BV 1.08
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 14
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026 Q2 2026 Q1 2026
Revenue 15.321M 3.004M 19.635M
Net profit -4.266M -20.186M -16.633M
Free cash flow -25.783M -3.962M -33.241M

Figure Q3 2026 Q2 2026 Q1 2026
Share price 8.28 13.45 13.37
Price performance 12m -0.82 -0.56 -0.52

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 3.67M
Cash and deposits (USD) 0.00 0.00
Right-of-use assets (USD) — 2.78M
Reported May 14, 2026 May 14, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

— First patient dosed with ATR 1072 in the Corventis™ Phase 1/2 clinical trial in PRKAG2 syndrome —

— Nonclinical data showed ATR 1072 reversed cardiac glycogen accumulation and improved features of PRKAG2 syndrome —

— Pro-forma cash balance at the end of September 2026 was $293.6 million with anticipated cash runway through 2028 —

SAN DIEGO, November 12, 2026 / PRNewswire/ – Atrium Therapeutics, Inc. (Nasdaq: RNA) (“Atrium,” “Atrium Therapeutics,” or the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent progress including dosing of the first patient in Corventis, its Phase 1/2 clinical trial of ATR 1072 in PRKAG2 syndrome, nonclinical data showing ATR 1072 reversed cardiac glycogen accumulation, and a $50 million private placement that extends its cash runway through 2028.

Atrium Therapeutics to Present Nonclinical Data Showing ATR 1072 Bull 2 Bear 0 Clinical/regulatory

Reversed and Improved Features of PRKAG2 Syndrome During HCMS

at AHA Scientific Sessions 2026

— ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation of

cardiac glycogen and cardiac hypertrophy —

— Data further reinforce scientific rationale for ATR 1072 targeting the root cause of

PRKAG2 syndrome —

— Poster presentation November 6 at 5:30 p.m. CT —

SAN DIEGO, Nov. 2, 2026 – Atrium Therapeutics, Inc. (Nasdaq: RNA) (the “Company”), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome during Hypertrophic Cardiomyopathy Medical Society at the American Heart Association Scientific Sessions 2026, taking place on November 6, 2026, in Chicago, Illinois.

“Our new nonclinical model reproduced many features of PRKAG2 syndrome, including cardiac glycogen accumulation in the heart,” said Husam Younis, Chief Scientific Officer of Atrium Therapeutics.

-- ATR 1072 impacted key characteristics of PRKAG2 syndrome, including accumulation of
cardiac glycogen and cardiac hypertrophy --

-- Data further reinforce scientific rationale for ATR 1072 targeting the root cause of
PRKAG2 syndrome --

-- Poster presentation November 6 at 5:30 p.m. CT --

SAN DIEGO, Nov. 2, 2026 /PRNewswire / -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, today announced that it will present new nonclinical data supporting its lead investigational therapy ATR 1072 for the potential treatment of PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome during Hypertrophic Cardiomyopathy Medical Society at the American Heart Association Scientific Sessions 2026, taking place on November 6, 2026, in Chicago, Illinois.

Atrium Therapeutics logo

"Our new nonclinical model reproduced many features of PRKAG2 syndrome, including cardiac glycogen accumulation in the heart," said Husam Younis, Chief Scientific Officer of Atrium Therapeutics. "We are encouraged to see that a mouse-specific version of ATR 1072 reversed cardiac glycogen accumulation and improved other key features of the disease. These findings continue to strengthen the scientific rationale for ATR 1072. We now look to the ongoing Phase 1/2 Corventis trial and expect initial proof of concept data in the second half of 2027."

The nonclinical results being presented at HCMS were generated in a new mouse model of PRKAG2 syndrome developed by Atrium that demonstrates key features of the disease, including cardiac glycogen accumulation, cardiac hypertrophy, and electrocardiogram (ECG) abnormalities. In the study, mice received a single dose of mATR 1072, a mouse surrogate of ATR 1072, after features of the disease had been established for three weeks. By targeting disease causing variant PRKAG2 mRNA in the heart, mATR 1072 treatment led to reversal of cardiac glycogen accumulation as well as improvement in other key features of the disease, including hypertrophy and ECG parameters.

Details of the HCMS Scientific Sessions poster:

Friday, November 6, 2026, at 5:30 p.m CT.

Targeting PRKAG2 mRNA with mATR 1072 to improve glycogen-storage cardiomyopathy in a mouse model of PRKAG2 syndrome 
Presentation Number: HCM32; Poster Board Number: 32

About PRKAG2 Syndrome

PRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by variants in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Variants enhance AMPK activity leading to abnormal glycogen accumulation in the heart, thickened heart muscles, electrical conduction problems, and arrhythmias. Based on current scientific literature estimates, there are at least 1,000 – 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment; no approved therapies exist to address the underlying genetic driver of disease.

About the Corventis™ Trial

Corventis™ is a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants living with PRKAG2 syndrome. The study will enroll approximately 37 participants across two parts: Part A, multiple ascending dose cohorts to characterize safety and support dose selection, and Part B, a single-arm expansion cohort at the recommended Phase 2 dose to further evaluate efficacy trends in cardiac structure and function. The study's primary endpoint is the incidence of treatment-emergent adverse events, with secondary and exploratory endpoints such as PRKAG2 mRNA reduction, siRNA tissue concentrations and plasma pharmacokinetics.

Additional information about the trial is available at www.corventistrial.com .

About Atrium Therapeutics

Atrium Therapeutics, Inc. (Nasdaq: RNA) is pioneering targeted delivery of ribonucleic acid (RNA) therapeutics to the heart to transform the standard of care for people living with cardiomyopathies. The Company's proprietary technology - designed at Avidity Biosciences, Inc. - combines the tissue selectivity of monoclonal antibodies (mAbs) and other targeted delivery ligands with the precision of oligonucleotides and is designed to selectively target the underlying drivers of genetically driven cardiac diseases through targeted, non-viral delivery of small interfering RNA (siRNA). This approach builds upon learnings from demonstrated delivery to skeletal muscle and applies it for efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. The Company's pipeline includes ATR 1072 for PRKAG2 syndrome, ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.

Prompts

Atrium Therapeutics, Inc. (ticker RNA), listed in United States.

Company History

Date Change Detail
— Different company Avidity Biosciences, Inc. (CIK 1599901) is a different company that has used this ticker. Its filings are not shown here.

ETFs Holding Atrium Therapeutics, Inc.

ETF Weight in ETF Shares Market value As of
FSEG 0.05% 216 $ 2,905.20 Jun 30, 2026
RESM 0.01% 20 $ 269.00 Jun 30, 2026
FESM 0.00% 11,112 $ 149.456K Jun 30, 2026
AVUS 0.00% 5,665 $ 36.426K Nov 16, 2026
AVIE 0.00% 14 $ 90.02 Nov 16, 2026